OVID
NASDAQ · Biotechnology
Ovid Therapeutics Inc
$2.84
-0.05 (-1.73%)
Open$2.87
Previous Close$2.89
Day High$2.91
Day Low$2.80
52W High$3.11
52W Low$0.55
Volume—
Avg Volume1.49M
Market Cap518.86M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,345.1% upside
Current
$2.84
$2.84
Target
$41.04
$41.04
$30.97
$41.04 avg
$66.83
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.23M | 10.78M | 31.11M |
| Net Income | -43,769,504 | -23,296,796 | -8,350,078 |
| Profit Margin | -240.1% | -228.1% | -26.8% |
| EBITDA | -105,977,052 | -59,541,190 | -13,566,183 |
| Free Cash Flow | — | — | -8,976,737 |
| Rev Growth | +69.1% | +69.1% | +19.5% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |